Search

Displaying results 851 - 860 of 4265 in total
  1. Drug

    Seproxetine

    go.drugbank.com/drugs/DB06731
    Experimental

    Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.

  2. Drug

    Amobarbital

    go.drugbank.com/drugs/DB01351
    ApprovedIllicit

    A barbiturate with hypnotic and sedative properties (but not antianxiety).

  3. Drug

    Eteplirsen

    go.drugbank.com/drugs/DB06014
    ApprovedInvestigational

    Eteplirsen was the first treatment for DMD approved by the FDA.[A244925] … [L40015] Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and premature death most commonly due to respiratory or cardiac complications.

  4. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    The cream formulation was first approved by the FDA in July 2022 [L42580] and by Health Canada in April 2023. … [L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018.[L37564] Roflumilast topical cream is indicated to treat plaque psoriasis.

  5. Drug

    Allopurinol

    go.drugbank.com/drugs/DB00437
    ApprovedInvestigational

    It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677]. … Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints [A175942].

  6. Drug

    Peanut oil

    go.drugbank.com/drugs/DB13964
    ApprovedWithdrawn

    The kernels are consumed roasted but a large percentage is used for the production of vegetable oil.

  7. Drug

    Eszopiclone

    go.drugbank.com/drugs/DB00402
    ApprovedInvestigational

    Eszopiclone was initially approved by the FDA in 2004.[L6769] … One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia.

  8. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    [A32025] About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. … Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 [A183062] for the treatment of narcolepsy with or without cataplexy.

  9. Drug

    Cefadroxil

    go.drugbank.com/drugs/DB01140
    ApprovedInvestigationalVet approvedWithdrawn

    Long-acting, broad-spectrum, water-soluble, cephalexin derivative.

  10. Drug

    Torasemide

    go.drugbank.com/drugs/DB00214
    ApprovedInvestigational

    [A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]